AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Pharmacological Screen to Identify Compounds That Facilitate NO signaling in Muscle With Deficient nNOS Localization and/or Activity

Detailed Technology Description: Technology DescriptionResearchers have discovered a newoption for treating muscular dystrophy and other diseases associated withmuscle wasting symptoms. This option consists of the administration ofsildenafil (or another inhibitor of phosphodiesterase 5A) in affected patients priorto exercise or similar activity. The effects of this treatment areattributed to the known mechanism of action for these agents, which is theprevention of cGMP degradation. cGMP is a key messenger for initiatingvasodilation and thus increasing blood flow. When this treatment is instituted,the cGMP persists longer in smooth muscle cells and the resulting vasodilationalso persists for a greater period of time. This increase in blood flow toactive muscles slows their rate of fatigue and limits the activity-inducedmuscle tissue damage associated with myopathic conditions.Advantages Novel mechanism of action. Phosphodiesterase inhibitors work via the preservation of cGMP in blood vessels, which initiates vasodilation. It is believed that the absence of vasodilation and the resulting lack of increased blood flow play a key role in rapid muscle fatigue and muscle cell breakdown.Well-established safety profile. Sildenafil and other phosphodiesterase inhibitors have been used clinically for many years and have shown themselves to be safe for long-term use.

*Abstract: Background
There are a variety of diseases thatcause muscle weakness and muscle tissue breakdown (myopathy). The most notableof these diseases are the muscular dystrophies, but can also include suchdiverse conditions as HIV infection cancer, and aging. The symptoms ofmyopathy have a variety of causes, but all result in various levels ofdebilitation to the patient. A treatment that could slow or prevent theprogression of muscle weakness from various causes would have significant valueto patients.

*Licensing: Email: uirf-marketing@uiowa.eduPhone: (319) 335-4546

Country/Region: USA

For more information, please click Here